146 related articles for article (PubMed ID: 17073582)
1. Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis.
Reginster JY; Gieschke R
Curr Drug Metab; 2006 Oct; 7(7):827-36. PubMed ID: 17073582
[TBL] [Abstract][Full Text] [Related]
2. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.
Pillai G; Gieschke R; Goggin T; Jacqmin P; Schimmer RC; Steimer JL
Br J Clin Pharmacol; 2004 Dec; 58(6):618-31. PubMed ID: 15563360
[TBL] [Abstract][Full Text] [Related]
3. Ibandronate in profile: drug characteristics and clinical efficacy.
Reginster JY; Neuprez A; Bruyère O
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):941-51. PubMed ID: 18624681
[TBL] [Abstract][Full Text] [Related]
4. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
Reginster JY
Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females.
Pillai G; Gieschke R; Goggin T; Barrett J; Worth E; Steimer JL
Int J Clin Pharmacol Ther; 2006 Dec; 44(12):655-67. PubMed ID: 17190376
[TBL] [Abstract][Full Text] [Related]
6. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Pyon EY
Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
[TBL] [Abstract][Full Text] [Related]
7. Ibandronate: a review of its use in the management of postmenopausal osteoporosis.
Frampton JE; Perry CM
Drugs; 2008; 68(18):2683-707. PubMed ID: 19093707
[TBL] [Abstract][Full Text] [Related]
8. Once-monthly dosing: an effective step forward.
Reid DM
Bone; 2006 Apr; 38(4 Suppl 1):S18-22. PubMed ID: 16533625
[TBL] [Abstract][Full Text] [Related]
9. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
Rossini M; Viapiana O; Gatti D; Adami S
Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
[TBL] [Abstract][Full Text] [Related]
10. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
Schimmer RC; Bauss F
Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
[TBL] [Abstract][Full Text] [Related]
11. Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.
Reginster JY
Expert Opin Pharmacother; 2005 Oct; 6(13):2301-13. PubMed ID: 16218890
[TBL] [Abstract][Full Text] [Related]
12. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
Delmas PD; Adami S; Strugala C; Stakkestad JA; Reginster JY; Felsenberg D; Christiansen C; Civitelli R; Drezner MK; Recker RR; Bolognese M; Hughes C; Masanauskaite D; Ward P; Sambrook P; Reid DM
Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
[TBL] [Abstract][Full Text] [Related]
13. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
[TBL] [Abstract][Full Text] [Related]
14. Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens.
Epstein S
Curr Osteoporos Rep; 2006 Mar; 4(1):14-20. PubMed ID: 16527003
[TBL] [Abstract][Full Text] [Related]
15. Application of modeling and simulation to a long-term clinical trial: a direct comparison of simulated data and data actually observed in Japanese osteoporosis patients following 3-year ibandronate treatment.
Nakai K; Iida S; Tobinai M; Hashimoto J; Kawanishi T
Clin Pharmacokinet; 2015 Mar; 54(3):295-304. PubMed ID: 25403846
[TBL] [Abstract][Full Text] [Related]
16. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
Miller PD; McClung MR; Macovei L; Stakkestad JA; Luckey M; Bonvoisin B; Reginster JY; Recker RR; Hughes C; Lewiecki EM; Felsenberg D; Delmas PD; Kendler DL; Bolognese MA; Mairon N; Cooper C
J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
[TBL] [Abstract][Full Text] [Related]
17. The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties.
Nakai K; Tobinai M; Hashimoto J; Iida S; Kawanishi T
Eur J Drug Metab Pharmacokinet; 2016 Apr; 41(2):139-47. PubMed ID: 25476995
[TBL] [Abstract][Full Text] [Related]
18. Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women.
Marathe DD; Marathe A; Mager DE
Biopharm Drug Dispos; 2011 Nov; 32(8):471-81. PubMed ID: 21953540
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
Eisman JA; Civitelli R; Adami S; Czerwinski E; Recknor C; Prince R; Reginster JY; Zaidi M; Felsenberg D; Hughes C; Mairon N; Masanauskaite D; Reid DM; Delmas PD; Recker RR
J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
